For example, NPM1 mutations and double CEBPA mutations are associated with favorable prognosis in cytogenetically normal AML (CN-AML) 2, 3, while DNMT3A and WT1 mutations are adverse prognostic factors 4, 5. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.